American Heart Journal
Volume 151, Issue 5 , Pages 975.e1-975.e9 , May 2006

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II

  • Christie M. Ballantyne, MD

      Affiliations

    • Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX
    • Corresponding Author InformationReprint requests: Christie M. Ballantyne, MD, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M.S. A-601, Houston, TX 77030.
    • ,
  • Marcelo Bertolami, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
    • ,
  • Hugo Ricardo Hernandez Garcia, MD

      Affiliations

    • Centro Medico Nacional de Occidente IMSS, Guadalajara, Mexico
    • ,
  • Daniel Nul, MD

      Affiliations

    • Instituto Medico Constituyentes, Buenos Aires, Argentina
    • ,
  • Evan A. Stein, MD

      Affiliations

    • MRL International, Highland Heights, KY
    • ,
  • Pierre Theroux, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • Robert Weiss, MD

      Affiliations

    • Androscoggin Cardiology Associates, Auburn, MI
    • ,
  • Valerie A. Cain, MS

      Affiliations

    • AstraZeneca, Wilmington, DE
    • ,
  • Joel S. Raichlen, MD

      Affiliations

    • AstraZeneca, Wilmington, DE

Received 12 September 2005 ,Accepted 14 December 2005.

  • Image Result

    Trial design. Treatment arms and number of patients randomized.

    Trial design. Treatment arms and number of patients randomized.

  • Image Result

    Differences in incremental least-squares mean percentage changes in LDL-C between week 8 and week 16 after switching to rosuvastatin (RSV) or remaining on atorvastatin (ATV) or simvastatin (SIM) for 8

    Differences in incremental least-squares mean percentage changes in LDL-C between week 8 and week 16 after switching to rosuvastatin (RSV) or remaining on atorvastatin (ATV) or simvastatin (SIM) for 8 weeks. (A) Switching to RSV 10 mg vs remaining on ATV 10 mg; (B) switching to RSV 20 mg vs remaining on ATV 20 mg; (C) switching to RSV 10 mg vs remaining on SIM 20 mg; (D) switching to RSV 20 mg vs remaining on SIM 40 mg. *Difference between incremental least-squares mean % changes in LDL-C from week 8 to week 16.

  • Image Result
    Proportions of patients achieving ATP III LDL-C goal <100 mg/dL at 16 weeks after switching to rosuvastatin (RSV) or remaining on atorvastatin (ATV) or simvastatin (SIM) after 8 weeks. *P < .001 for w

    Proportions of patients achieving ATP III LDL-C goal <100 mg/dL at 16 weeks after switching to rosuvastatin (RSV) or remaining on atorvastatin (ATV) or simvastatin (SIM) after 8 weeks. *P < .001 for within-arm comparison of rosuvastatin vs atorvastatin or simvastatin.

PII: S0002-8703(06)00016-0

doi: 10.1016/j.ahj.2005.12.013

American Heart Journal
Volume 151, Issue 5 , Pages 975.e1-975.e9 , May 2006

Article Tools

* Image Usage & Resolution